Age

18–59

Sex

ALL

Healthy volunteers

Not accepted

Patients with a histopathologically confirmed diagnosis of UC.
With mild and moderate disease.
Patients treated with only doses of 5-aminosalicylates (5-ASA)
BMI, 18 to 34.9 kg/m2
Born in Mexico the last two generations
Each patient will be asked to sign and date the consent form, to indicate that you agree to participate.

Patient with associated diseases such as diabetes mellitus, hypertension, dyslipidemia, atherosclerosis and malabsorption syndrome.
With autoimmune diseases (lupus, HIV, cancer and hepatitis), colitis (infectious, post-radiation, post-drug, indeterminate) and Crohn's Disease.
If the patient use drugs that inhibit fat absorption.
Patients after partial or total resection of stomach or small intestine.
Steroid users.
Patients in remission histology, clinical and endoscopic.
Patients treated with FAn-3,6 or 9.

Effect of FAn-7 in UC Activity